biostudies-literatureOrtiz JRNCATS NIH HHSNIAID NIH HHS3253-3262https://www.ebi.ac.uk/biostudies/studies/S-EPMC9897630biostudies-literatureUnknown40(23)<h4>Background</h4>Influenza A/H7N9 viruses have pandemic potential.<h4>Methods</h4>We conducted an open-label, randomized, controlled trial of AS03-adjuvanted 2017 inactivated influenza A/H7N9 vaccine (H7N9 IIV) in healthy adults. Group 1 received H7N9 IIV and seasonal quadrivalent influenza vaccine (IIV4) simultaneously, followed by H7N9 IIV three weeks later. Group 2 received IIV4 alone and then two doses of H7N9 IIV at three-week intervals. Group 3 received one dose of IIV4. We used hemagglutination inhibition (HAI) and microneutralization (MN) assays to measure geometric mean titers and seroprotection (≥1:40 titer) to vaccine strains and monitored for safety.<h4>Results</h4>Among 149 subjects, seroprotection by HAI three weeks after H7N9 IIV dose 2 was 51% (95 %CI 37%-65%) for Group 1VaccineSafety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.PMC9897630UM1 AI148372HHSN272201300023IUL1 TR003098HHSN272201200003I75N93021C00012HHSN272201300016CHHSN272201300023CHHSN272201300016IR01 AI145332HHSN272200800057CNeuzil KMOrtiz JROverton ETWegel AGoepfert PACross KChen WHBuddy Creech CLogan HLParker SSpearman PWDickey MfalseSafety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.<h4>Background</h4>Influenza A/H7N9 viruses have pandemic potential.<h4>Methods</h4>We conducted an open-label, randomized, controlled trial of AS03-adjuvanted 2017 inactivated influenza A/H7N9 vaccine (H7N9 IIV) in healthy adults. Group 1 received H7N9 IIV and seasonal quadrivalent influenza vaccine (IIV4) simultaneously, followed by H7N9 IIV three weeks later. Group 2 received IIV4 alone and then two doses of H7N9 IIV at three-week intervals. Group 3 received one dose of IIV4. We used hemagglutination inhibition (HAI) and microneutralization (MN) assays to measure geometric mean titers and seroprotection (≥1:40 titer) to vaccine strains and monitored for safety.<h4>Results</h4>Among 149 subjects, seroprotection by HAI three weeks after H7N9 IIV dose 2 was 51% (95 %CI 37%-65%) for Group 12022-01-01T00:00:00Z2022 May2026-05-28T19:00:44.545Z2025-02-19T00:13:26.072ZS-EPMC98976303546598310.1016/j.vaccine.2022.03.055